Secondary hormonal therapy for prostate cancer: what lies on the horizon?
Authors:
Open Access
- 8 October 2007
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 101 (3) , 271-274
Abstract
Androgen deprivation therapy with medical or surgical castration is generally the first‐line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate‐resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.Keywords
This publication has 21 references indexed in Scilit:
- Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B StudyClinical Cancer Research, 2007
- The Case for Secondary Hormonal Therapies in the Chemotherapy AgeJournal of Urology, 2006
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005
- Androgen Receptor in Prostate CancerEndocrine Reviews, 2004
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Partial Hormone Resistance in Mice with Disruption of the Steroid Receptor Coactivator-1 (SRC-1) GeneScience, 1998
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancerThe American Journal of Medicine, 1995
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990